The synergistic activity of tigecycline-based combinations against multidrug-resistant Acinetobacter baumannii -caused bloodstream infections

High-dose tigecycline combined with meropenem displayed an excellent synergistic effect against BSIs caused by tigecycline-susceptible but not non-tigecycline-susceptible MDRAB, therefore providing a promising treatment choice for tigecycline-susceptible MDRAB BSIs in the clinic.